Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has shared an update.
Alligator Bioscience AB has announced the preliminary results of its TO 13 warrants exercise, which concluded on September 15, 2025. The exercise saw a significant uptake, with approximately 90.6% of the warrants exercised, resulting in the subscription of 8,903,880 new ordinary shares and raising about SEK 27.8 million before costs. This development is expected to bolster the company’s financial position and support its ongoing research and development efforts in the biotechnology sector.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company specializing in the development of clinical-stage tumor-directed antibody drugs targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive nature of the tumor microenvironment, offering potential benefits for cancer patients. The company’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development following promising results in metastatic pancreatic cancer trials. Alligator Bioscience is listed on Nasdaq Stockholm and is based in Lund, Sweden.
Average Trading Volume: 500,991
Technical Sentiment Signal: Sell
Current Market Cap: SEK137.5M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.